Arena gets South Korea nod to market Belviq with local firm Ildong Pharmaceuticals

SINGAPORE--Ildong Pharmaceuticals said South Korea's Ministry of Food and Drug Safety has granted approval for it to market the Arena Pharmaceuticals ($ARNA) weight-loss drug, Belviq (lorcaserin).

Arena's South Korea unit, Arena Pharmaceuticals GambH, arranged the licensing deal and is to supply the drug to Ildong in exchange for a $3 million milestone payment from Ildong. Ildong also is to handle distribution.

The approval indication is for use as an adjunct to a reduced-calorie diet and increased physical activity for weight management, Arena said. The drug is restricted to adults with an initial body mass index of 30 kg/m2 and at least one comorbid condition such as hypertension or Type 2 diabetes.

- read the release

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.